Atossa Therapeutics (ATOS) Retained Earnings (2011 - 2026)
Atossa Therapeutics (ATOS) posted quarterly Retained Earnings of $286.6 million for Q1 2026, up 9.45% year-over-year from $261.8 million in Q1 2025, and little changed quarter-over-quarter from $285.8 million in Q4 2025.
Atossa Therapeutics (ATOS) Retained Earnings (2011 - 2026) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Retained Earnings for 16 consecutive years, with $286.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 9.45% year-over-year to $286.6 million; the TTM figure through Mar 2026 stood at $286.6 million (up 9.45% YoY), while the FY2025 annual figure was $285.8 million, up 234.96% from the prior year.
- Retained Earnings was little changed at $286.6 million in Q1 2026 per ATOS's latest filing, from $285.8 million in the prior quarter.
- Across five years, Retained Earnings topped out at $286.6 million in Q1 2026 and bottomed at -$235.6 million in Q3 2025.
- Historically, Retained Earnings has averaged -$20.9 million across 5 years, with a median of -$148.7 million in 2022.
- Annual changes were most pronounced in 2023 — Retained Earnings jumped 263.89% — and 2025, when it sank 191.43%.
- Atossa Therapeutics' Retained Earnings stood at -$156.2 million in 2022, then surged by 263.89% to $256.0 million in 2023, then plunged by 182.74% to -$211.8 million in 2024, then soared by 234.96% to $285.8 million in 2025, then grew by 0.25% to $286.6 million in 2026.
- Business Quant data shows ATOS's Retained Earnings at $286.6 million in Q1 2026, $285.8 million in Q4 2025, and -$235.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 4.38 Bn |
| 10 | Atossa Therapeutics | 22.76 Mn | 22.76 Mn | - | 291.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 291.15 Mn |
| Mar 31, 2026 | 286.56 Mn |
| Dec 31, 2025 | 285.84 Mn |
| Sep 30, 2025 | -235.63 Mn |
| Jun 30, 2025 | -226.93 Mn |
| Mar 31, 2025 | 261.82 Mn |
| Dec 31, 2024 | -211.79 Mn |
| Sep 30, 2024 | 257.72 Mn |
| Jun 30, 2024 | 256.98 Mn |
| Mar 31, 2024 | -192.17 Mn |
| Dec 31, 2023 | 255.99 Mn |
| Sep 30, 2023 | -178.53 Mn |
| Jun 30, 2023 | -172.31 Mn |
| Mar 31, 2023 | -162.48 Mn |
| Dec 31, 2022 | -156.19 Mn |
| Sep 30, 2022 | -148.70 Mn |
| Jun 30, 2022 | -140.69 Mn |
| Mar 31, 2022 | -134.02 Mn |
| Dec 31, 2021 | -129.23 Mn |
| Sep 30, 2021 | -124.40 Mn |